See the DrugPatentWatch profile for Calquence
Calquence, an AstraZeneca medication, achieved global sales of $1.689 billion in 2022 [1]. This represents a significant increase from its 2021 sales of $954 million [1]. The drug's revenue stream has grown substantially since its launch.
How is Calquence performing in key markets?
In 2022, Calquence generated $1.023 billion in the United States and $666 million in international markets [1]. This indicates a strong performance in the US, which is its largest market by revenue.
When does Calquence's patent protection expire?
The patent landscape for Calquence is complex, involving multiple patents covering different aspects of the drug, including its composition of matter, methods of use, and manufacturing processes. Detailed information on specific patent expiry dates and potential challenges can be found on DrugPatentWatch.com [2]. The exclusivity for a drug can be influenced by various patents and regulatory exclusivities, which may not always align with the expiration of a primary composition of matter patent.
What are the key indications for Calquence?
Calquence (acalabrutinib) is approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [3]. It is also indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy [3]. Furthermore, it is approved for treatment-naïve CLL/SLL [3].
Who are Calquence's main competitors?
Calquence competes in the B-cell malignancy market. Key competitors include other Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors. While specific competitor sales figures are not provided here, the market is dynamic with several pharmaceutical companies offering treatments for CLL/SLL and MCL [4].
What is the mechanism of action for Calquence?
Calquence is a targeted therapy that works by inhibiting Bruton's tyrosine kinase (BTK) [3]. BTK is a protein found on B cells that plays a role in cell signaling, survival, and proliferation. By blocking BTK, Calquence can help to slow or stop the growth of cancerous B cells.
What clinical trials support Calquence's approvals?
The approvals for Calquence are supported by data from several clinical trials. For MCL, the ELEVATE-MCL trial demonstrated efficacy [3]. For CLL/SLL, the ELEVATE-CL trial contributed to its approval in treatment-naïve patients, while earlier trials supported its use in relapsed/refractory settings [3].
---
Sources:
[1] AstraZeneca. (2023). AstraZeneca Full Year Results 2022. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-full-year-results-2022.html
[2] DrugPatentWatch.com. (n.d.). Calquence Patent Information. Retrieved from https://www.drugpatentwatch.com/
[3] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from https://www.fda.gov/drugs/
[4] National Cancer Institute. (n.d.). Targeted Therapy Drugs. Retrieved from https://www.cancer.gov/